Abstract：【Objective】To detect the expression of tumor stem cell marker CD133 and micro vessel density (MVD) in triple negative breast carcinoma (TNBC), and to analyze their clinical value.【Methods】A total of 41 patients with triple-negative breast cancer were enrolled in our hospital from January 2010 to January 2012 for this study. CD133 expression and MVD count were measured by immunohistochemical method ElivisionTM plus, and the follow-up data of all patients were arranged and analyzed.【Results】There were significant differences in age, menstrual status, lymph node metastasis and histological grade between TNBC patients and non - TNBC patients (P<0.05).However, there were no significant differences in tumor size, pathological type and clinical stage (P>0.05). Out of the total 41 TNBC cases, 18 had CD133 positive expression, accounting for 43.90% of the total samples. In these cases, the tumor size, clinical stage and lymph node metastasis were closely related to the positive rate of CD133 (P<0.05). The mean MVD count of TNBC patients was (20.95 ± 7.8) which was significantly higher than that of non-TNBC group (15.02 ± 9.3); the difference was significant (t=3.916, P<0.05).MVD counts in lymph node metastasis and clinical staging were statistically significant (P<0.05). The MVD value of CD133 positive in TNBC patients was (23.34 ± 8.4), which was significantly higher than that of CD133 negative (18.11 ± 5.5), and the difference was significant (t=2.403, P<0.05). The mean time of disease-free survival (DFS) and overall survival (OS) time of CD133 positive expression in TNBC were (25.5 ± 3.6) months and (32.3±2.5) months, respectively. These were significantly lower than those of CD133 negative expression in TNBC DFS (58.2 ± 4.2) months and OS (54.6 ± 3.3) months, respectively; The difference was significant (P<0.05). In this study, the median value of MVD in 41 patients with TNBC was 21. Our results showed that the 3-year and 5-year survival rates of MVD≥21 were significantly lower than those of MVD<21; the difference was significant (P<0.05 ).【Conclusion】CD133 expression and MVD count are closely related to lymphatic metastasis and clinical stage in TNBC patients. Therefore, the clinical progress and prognosis of TNBC patients can be determined by measuring CD133 expression and MVD count and is worthy of clinical application.
喻宏,李晓星,贾晓敏. CD133、MVD在三阴乳腺癌组织中的表达及其意义[J]. 医学临床研究, 2017, 34(10): 1938-1940.
YU Hong, LI Xiao-xing, JIA Xiao-min. Expression of CD133 and MVD in Triple-Negative Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2017, 34(10): 1938-1940.
[1]郑红梅,李祥,金立亭,等.三阴性乳腺癌基因学分子分型和个体化治疗新进展[J].中华肿瘤防治杂志,2016,23(17):1198-1204. [2]赵淑红,曹席明,于娇,等.转移性三阴乳腺癌89例临床特点及生存分析[J].陕西医学杂志,2016,45(7):859-861. [3]陈曦,吴晶晶,张妍,等.三阴性乳腺癌临床病理特征及与药物敏感度蛋白的相关性[J].肿瘤防治研究,2014,41(5):439-442. [4]Hberle L,Hein A,Rübner M,et al.Predicting triple-negative breast cancer subtype using multiple single nucleotide polymorphisms for breast cancer risk and several variable selection methods [J].Geburtshilfe Frauenheilkd,2017,77(6):667-678. [5]李索妮,姚煜,南克俊.三阴性乳腺癌治疗进展[J].现代肿瘤医学,2014,22(1):197-200. [6]范海浪,吕明生.15例三阴乳腺癌临床分析研究[J].中华全科医学,2014,12(9):1427. [7]李佰君,孟春,张雪琛.三阴性乳腺癌的临床特点及研究进展[J].中国肿瘤临床与康复,2014,21(5):636-638. [8]周勇.三阴型乳腺癌临床病理特征及预后分析[J].检验医学与临床,2014,11(11):1572-1573. [9]陆国芬,张辉挺,马德奎,等.我国三阴型乳腺癌临床病理特征与预后的Meta分析[J].中国医药导报,2016,13(35):96-101. [10]付汐,卢国英,李志辉,等.干细胞标记物CD133及CK19在鼻咽癌的表达及其临床意义[J].医学临床研究,2014,31(8):1485-1487. [11]宋云骏,姜林鹤,刘运江,等.CD133在乳腺癌新辅助化疗后的表达及其临床意义[J].临床和实验医学杂志,2014,13(4):297-300. [12]张文进,李云涛,陈鑫,等.CD31标记的微血管密度在乳腺浸润性导管癌中的表达及其临床意义[J].中华乳腺病杂志电子版,2014,8(1):19-22. [13]文显梅,周木秀,郭勇,等.三阴乳腺癌组织表皮生长因子受体表达及其与微血管密度和微淋巴管密度的相关性[J].微循环学杂志,2016,26(2):5-8. [14]宋一民,王英姿,吕新全,等.乳腺浸润性导管癌组织中ALDH1+/CD133+干细胞样细胞与血管生成的关系[J].肿瘤防治研究,2015,42(7):706-711.
2017, Vol. 34 
